Drug Trial Radar · NCT04678648
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
134
Planned (sponsor's estimate)
Start
Mar 3, 2021
Primary completion
Mar 16, 2027
Study completion Mar 17, 2028
Sponsor
- Lead sponsor
- RasCal Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.
Conditions
- Advanced Malignant Solid Neoplasm
- RAS Mutation
- Lung Cancer
- Colon Cancer
- Glioblastoma
- Pancreatic Cancer
Interventions
RSC-1255 Dose EscalationDrug
Phase 1a will enroll 40-80 participants to identify the dose limiting toxicity (DLT), recommended Phase 1b dose, and the safety and tolerability of RSC-1255. RSC-1255 is administered orally twice daily, with and without food. Each cycle is 21 days.
RSC-1255 Dose ExpansionDrug
Phase 1b will enroll 48-94 participants to further characterize the safety, pharmacology, and clinical efficacy of RSC-1255. RSC-1255 is administered orally twice daily alone or in combination with continuous hydroxychloroquine, with food. Each cycle is 21 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD) for RSC-1255 as monotherapyTime frame: Approximately 30 months
- Recommended Phase 2 Dose (RP2D) for RSC-1255 as monotherapyTime frame: Approximately 12 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of California, Los Angeles (UCLA) Department of Medicine - Hematology/Oncology
Los Angeles, California · Recruiting
Sarah Cannon, SCRI Oncology Partners - Health One
Denver, Colorado · Recruiting
Sarah Cannon, SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.